{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363107369020184832.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/psp4.12500"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12500"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/psp4.12500"}},{"identifier":{"@type":"URI","@value":"https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12500"}}],"dc:title":[{"@value":"Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>MonolixSuite is a software widely used for model‐based drug development. It contains interconnected applications for data visualization, noncompartmental analysis, nonlinear mixed effect modeling, and clinical trial simulations. Its main assets are ease of use via an interactive graphical interface, computation speed, and efficient parameter estimation even for complex models. This tutorial presents a step‐by‐step pharmacokinetic (PK) modeling workflow using MonolixSuite, including how to visualize the data, set up a population PK model, estimate parameters, and diagnose and improve the model incrementally.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383107369020184833","@type":"Researcher","foaf:name":[{"@value":"Pauline Traynard"}],"jpcoar:affiliationName":[{"@value":"Lixoft Antony France"}]},{"@id":"https://cir.nii.ac.jp/crid/1383107369020184832","@type":"Researcher","foaf:name":[{"@value":"Géraldine Ayral"}],"jpcoar:affiliationName":[{"@value":"Lixoft Antony France"}]},{"@id":"https://cir.nii.ac.jp/crid/1383107369020184835","@type":"Researcher","foaf:name":[{"@value":"Monika Twarogowska"}],"jpcoar:affiliationName":[{"@value":"Lixoft Antony France"}]},{"@id":"https://cir.nii.ac.jp/crid/1383107369020184834","@type":"Researcher","foaf:name":[{"@value":"Jonathan Chauvin"}],"jpcoar:affiliationName":[{"@value":"Lixoft Antony France"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"21638306"},{"@type":"EISSN","@value":"21638306"}],"prism:publicationName":[{"@value":"CPT: Pharmacometrics & Systems Pharmacology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2020-03-31","prism:volume":"9","prism:number":"4","prism:startingPage":"198","prism:endingPage":"210"},"reviewed":"false","dc:rights":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12500"},{"@id":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/psp4.12500"},{"@id":"https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12500"}],"createdAt":"2020-02-09","modifiedAt":"2023-09-06","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050007846241174272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050569000714702208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2"}]},{"@id":"https://cir.nii.ac.jp/crid/1050570796221740288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Revisiting the guidelines for ending isolation for COVID-19 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017279878288768","@type":"Article","resourceType":"preprint","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865540235136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Public Health Impact of Paxlovid as Treatment for COVID-19, United States"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905635521664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Machine Learning Prediction and Validation of Plasma Concentration–Time Profiles"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567628647040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861705609971328","@type":"Article","resourceType":"preprint","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869854345254272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Stratifying and predicting progression to acute liver failure during the early phase of acute liver injury"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/psp4.12500"},{"@type":"CROSSREF","@value":"10.1101/2022.07.05.22277283_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.1371/journal.pmed.1003660_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.7554/elife.69340_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.1371/journal.pbio.3001128_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.3201/eid3002.230835_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.1021/acs.molpharmaceut.4c01431_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.1098/rsif.2020.0947_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.1101/2022.06.11.22276266_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"},{"@type":"CROSSREF","@value":"10.1093/pnasnexus/pgaf004_references_DOI_1OfnlrXNYAbzDFmlOhL1GRDtHBh"}]}